Novo Nordisk Statistics

Total Valuation

Novo Nordisk has a market cap or net worth of CAD 249.87 billion. The enterprise value is 272.10 billion.

Market Cap	249.87B
Enterprise Value	272.10B

Important Dates

The next confirmed earnings date is Wednesday, May 6, 2026.

Earnings Date	May 6, 2026
Ex-Dividend Date	Mar 30, 2026

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.34%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	28.21%
Float	3.18B

Valuation Ratios

The trailing PE ratio is 11.32 and the forward PE ratio is 12.57.

PE Ratio	11.32
Forward PE	12.57
PS Ratio	3.75
PB Ratio	5.97
P/TBV Ratio	18.11
P/FCF Ratio	19.66
P/OCF Ratio	9.73
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.21, with an EV/FCF ratio of 21.41.

EV / Earnings	12.32
EV / Sales	4.12
EV / EBITDA	8.21
EV / EBIT	9.05
EV / FCF	21.41

Financial Position

The company has a current ratio of 0.80, with a Debt / Equity ratio of 0.67.

Current Ratio	0.80
Quick Ratio	0.54
Debt / Equity	0.67
Debt / EBITDA	0.85
Debt / FCF	2.22
Interest Coverage	33.42

Financial Efficiency

Return on equity (ROE) is 60.70% and return on invested capital (ROIC) is 41.13%.

Return on Equity (ROE)	60.70%
Return on Assets (ROA)	17.43%
Return on Invested Capital (ROIC)	41.13%
Return on Capital Employed (ROCE)	42.97%
Weighted Average Cost of Capital (WACC)	5.42%
Revenue Per Employee	963,417
Profits Per Employee	319,308
Employee Count	69,505
Asset Turnover	0.61
Inventory Turnover	1.20

Taxes

In the past 12 months, Novo Nordisk has paid 6.06 billion in taxes.

Income Tax	6.06B
Effective Tax Rate	21.53%

Stock Price Statistics

The stock price has decreased by -37.17% in the last 52 weeks. The beta is 0.27, so Novo Nordisk's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	-37.17%
50-Day Moving Average	4.08
200-Day Moving Average	5.31
Relative Strength Index (RSI)	59.05
Average Volume (20 Days)	51,787

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Novo Nordisk had revenue of CAD 66.62 billion and earned 22.08 billion in profits. Earnings per share was 4.96.

Revenue	66.62B
Gross Profit	54.90B
Operating Income	30.31B
Pretax Income	28.14B
Net Income	22.08B
EBITDA	33.04B
EBIT	30.31B
Earnings Per Share (EPS)	4.96

Balance Sheet

The company has 5.81 billion in cash and 28.23 billion in debt, giving a net cash position of -22.42 billion.

Cash & Cash Equivalents	5.81B
Total Debt	28.23B
Net Cash	-22.42B
Net Cash Per Share	n/a
Equity (Book Value)	41.83B
Book Value Per Share	9.41
Working Capital	-9.31B

Cash Flow

In the last 12 months, operating cash flow was 25.67 billion and capital expenditures -12.96 billion, giving a free cash flow of 12.71 billion.

Operating Cash Flow	25.67B
Capital Expenditures	-12.96B
Depreciation & Amortization	2.71B
Net Borrowing	5.30B
Free Cash Flow	12.71B
FCF Per Share	n/a

Margins

Gross margin is 82.41%, with operating and profit margins of 45.50% and 33.14%.

Gross Margin	82.41%
Operating Margin	45.50%
Pretax Margin	42.24%
Profit Margin	33.14%
EBITDA Margin	49.60%
EBIT Margin	45.50%
FCF Margin	19.08%

Dividends & Yields

This stock pays an annual dividend of 0.04, which amounts to a dividend yield of 0.96%.

Dividend Per Share	0.04
Dividend Yield	0.96%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	50.53%
Buyback Yield	0.34%
Shareholder Yield	1.30%
Earnings Yield	8.84%
FCF Yield	5.09%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Novo Nordisk has an Altman Z-Score of 5.15 and a Piotroski F-Score of 5.

Altman Z-Score	5.15
Piotroski F-Score	5